Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 10-Oct-24 4:06 PM View:  | Garg Pushkal CMO & EVP Dev & Med Affairs | Alnylam Pharmaceuticals Inc. (ALNY) | 08-Oct-24 | Grant | 96 | -- | -- | < 1% 16.29K to 16.39K | |
| 22-Aug-24 8:01 PM View: | Greenstreet Yvonne Chief Executive Officer Director | Alnylam Pharmaceuticals Inc. (ALNY) | 20-Aug-24 | Option Exercise | 15,000 | $85.00 | $1,275,000.00 | 20% 73.85K to 88.85K | |
| 22-Aug-24 8:01 PM View: | Greenstreet Yvonne Chief Executive Officer Director | Alnylam Pharmaceuticals Inc. (ALNY) | 20-Aug-24 | Planned Option Sale | 15,000 | $280.00 | $4,200,000.00 | (17%) 88.85K to 73.85K | |
| 14-Aug-24 4:12 PM View: | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Alnylam Pharmaceuticals Inc. (ALNY) | 12-Aug-24 | Planned Option Sale | 20,725 | $270.99 | $5,616,230.00 | (58%) 35.44K to 14.72K | |
| 14-Aug-24 4:12 PM View: | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Alnylam Pharmaceuticals Inc. (ALNY) | 12-Aug-24 | Option Exercise | 20,725 | $89.09 | $1,846,430.00 | 141% 14.72K to 35.44K | |
| 14-Aug-24 4:12 PM View: | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Alnylam Pharmaceuticals Inc. (ALNY) | 12-Aug-24 | Sale (Planned) | 1,300 | $270.99 | $352,285.00 | (9%) 14.72K to 13.42K | |
| 08-Aug-24 4:10 PM View: | Ausiello Dennis A Director | Alnylam Pharmaceuticals Inc. (ALNY) | 06-Aug-24 | Option Exercise | 20,250 | $119.68 | $2,423,450.00 | 557% 3.64K to 23.89K | |
| 08-Aug-24 4:10 PM View: | Ausiello Dennis A Director | Alnylam Pharmaceuticals Inc. (ALNY) | 06-Aug-24 | Planned Option Sale | 20,250 | $262.00 | $5,305,590.00 | (85%) 23.89K to 3.64K | |
| 02-Aug-24 8:01 PM View: | Greenstreet Yvonne Chief Executive Officer Director | Alnylam Pharmaceuticals Inc. (ALNY) | 01-Aug-24 | Option Exercise | 15,148 | $85.00 | $1,287,580.00 | 21% 73.85K to 89.0K | |
| 02-Aug-24 8:01 PM View: | Greenstreet Yvonne Chief Executive Officer Director | Alnylam Pharmaceuticals Inc. (ALNY) | 01-Aug-24 | Planned Option Sale | 15,148 | $270.00 | $4,089,960.00 | (17%) 89.0K to 73.85K | |
| 12-Jul-24 8:02 PM View: | Greenstreet Yvonne Chief Executive Officer Director | Alnylam Pharmaceuticals Inc. (ALNY) | 11-Jul-24 | Private Sale (Planned) | 7,093 | $261.00 | $1,851,270.00 | (9%) 80.94K to 73.85K | |
| 27-Jun-24 4:04 PM View: | Schulman Amy W Director | Alnylam Pharmaceuticals Inc. (ALNY) | 25-Jun-24 | Option Exercise | 8,500 | $131.21 | $1,115,280.00 | 101% 8.44K to 16.94K | |
| 26-Jun-24 4:27 PM View: | Greenstreet Yvonne Chief Executive Officer Director | Alnylam Pharmaceuticals Inc. (ALNY) | 25-Jun-24 | Sale | 8,301 | $230.99 | $1,917,480.00 | (9%) 89.24K to 80.94K | |
| 26-Jun-24 4:26 PM View: | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Alnylam Pharmaceuticals Inc. (ALNY) | 25-Jun-24 | Sale | 1,198 | $230.99 | $276,731.00 | (8%) 15.92K to 14.72K | |
| 26-Jun-24 4:26 PM View: | Tanguler Tolga EVP, Chief Commercial Officer | Alnylam Pharmaceuticals Inc. (ALNY) | 25-Jun-24 | Sale | 1,605 | $230.99 | $370,747.00 | (12%) 13.27K to 11.66K | |
| 26-Jun-24 4:28 PM View: | Garg Pushkal CMO & EVP Dev & Med Affairs | Alnylam Pharmaceuticals Inc. (ALNY) | 25-Jun-24 | Sale | 2,103 | $230.99 | $485,773.00 | (11%) 18.39K to 16.29K | |
| 27-Jun-24 4:04 PM View: | Schulman Amy W Director | Alnylam Pharmaceuticals Inc. (ALNY) | 25-Jun-24 | Planned Option Sale | 8,500 | $240.00 | $2,040,000.00 | (50%) 16.94K to 8.44K | |
| 26-Jun-24 4:26 PM View: | Poulton Jeffrey V. EVP, Chief Financial Officer | Alnylam Pharmaceuticals Inc. (ALNY) | 25-Jun-24 | Sale | 1,605 | $230.99 | $370,747.00 | (5%) 30.55K to 28.95K | |
| 26-Jun-24 4:26 PM View: | Tanguler Tolga EVP, Chief Commercial Officer | Alnylam Pharmaceuticals Inc. (ALNY) | 24-Jun-24 | Grant | 3,278 | -- | -- | 33% 9.99K to 13.27K | |
| 26-Jun-24 4:28 PM View: | Pyott David E I Director | Alnylam Pharmaceuticals Inc. (ALNY) | 24-Jun-24 | Option Exercise | 32,450 | $80.76 | $2,620,610.00 | 116% 28.04K to 60.49K | |
| 26-Jun-24 4:28 PM View: | Garg Pushkal CMO & EVP Dev & Med Affairs | Alnylam Pharmaceuticals Inc. (ALNY) | 24-Jun-24 | Grant | 4,295 | -- | -- | 30% 14.1K to 18.39K | |
| 26-Jun-24 4:27 PM View: | Greenstreet Yvonne Chief Executive Officer Director | Alnylam Pharmaceuticals Inc. (ALNY) | 24-Jun-24 | Grant | 16,953 | -- | -- | 23% 72.29K to 89.24K | |
| 26-Jun-24 4:28 PM View: | Pyott David E I Director | Alnylam Pharmaceuticals Inc. (ALNY) | 24-Jun-24 | Planned Option Sale | 32,450 | $220.69 | $7,161,360.00 | (54%) 60.49K to 28.04K | |
| 26-Jun-24 4:26 PM View: | Poulton Jeffrey V. EVP, Chief Financial Officer | Alnylam Pharmaceuticals Inc. (ALNY) | 24-Jun-24 | Grant | 3,278 | -- | -- | 12% 27.28K to 30.55K | |
| 26-Jun-24 4:26 PM View: | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Alnylam Pharmaceuticals Inc. (ALNY) | 24-Jun-24 | Grant | 2,498 | -- | -- | 19% 13.42K to 15.92K | |
| 31-May-24 7:00 PM View: | Schulman Amy W Director | Alnylam Pharmaceuticals Inc. (ALNY) | 29-May-24 | Planned Option Sale | 21,700 | $148.60 | $3,224,550.00 | (72%) 30.14K to 8.44K | |
| 31-May-24 7:00 PM View: | Schulman Amy W Director | Alnylam Pharmaceuticals Inc. (ALNY) | 29-May-24 | Option Exercise | 30,000 | $66.83 | $2,004,900.00 | 22059% 0.14K to 30.14K | |
| 05-Mar-24 4:20 PM View: | Greenstreet Yvonne Chief Executive Officer Director | Alnylam Pharmaceuticals Inc. (ALNY) | 01-Mar-24 | Grant | 23,754 | -- | -- | 49% 48.53K to 72.29K | |
| 05-Mar-24 4:21 PM View: | Poulton Jeffrey V. EVP, Chief Financial Officer | Alnylam Pharmaceuticals Inc. (ALNY) | 01-Mar-24 | Grant | 7,741 | -- | -- | 40% 19.54K to 27.28K | |
| 05-Mar-24 4:22 PM View: | Tanguler Tolga EVP, Chief Commercial Officer | Alnylam Pharmaceuticals Inc. (ALNY) | 01-Mar-24 | Grant | 4,751 | -- | -- | 91% 5.24K to 9.99K | |
| 05-Mar-24 4:21 PM View: | Garg Pushkal CMO & EVP Dev & Med Affairs | Alnylam Pharmaceuticals Inc. (ALNY) | 01-Mar-24 | Grant | 4,751 | -- | -- | 51% 9.35K to 14.1K | |
| 01-Mar-24 4:12 PM View: | Sharp Philip A Director | Alnylam Pharmaceuticals Inc. (ALNY) | 29-Feb-24 | Planned Option Sale | 30,000 | $151.34 | $4,540,070.00 | (10%) 296.9K to 266.9K | |
| 01-Mar-24 4:12 PM View: | Sharp Philip A Director | Alnylam Pharmaceuticals Inc. (ALNY) | 29-Feb-24 | Option Exercise | 30,000 | $59.25 | $1,777,500.00 | 11% 266.9K to 296.9K | |
| 29-Feb-24 4:18 PM View: | Greenstreet Yvonne Chief Executive Officer Director | Alnylam Pharmaceuticals Inc. (ALNY) | 28-Feb-24 | Option Sale | 2,932 | $155.31 | $455,357.00 | (6%) 51.47K to 48.53K | |
| 29-Feb-24 4:18 PM View: | Poulton Jeffrey V. EVP, Chief Financial Officer | Alnylam Pharmaceuticals Inc. (ALNY) | 28-Feb-24 | Option Sale | 574 | $155.30 | $89,144.60 | (3%) 20.11K to 19.54K | |
| 29-Feb-24 4:16 PM View: | Franchini Indrani Lall EVP, CLO & Secretary | Alnylam Pharmaceuticals Inc. (ALNY) | 28-Feb-24 | Option Sale | 329 | $155.30 | $51,094.50 | (7%) 4.46K to 4.13K | |
| 29-Feb-24 4:18 PM View: | Tanguler Tolga EVP, Chief Commercial Officer | Alnylam Pharmaceuticals Inc. (ALNY) | 28-Feb-24 | Option Sale | 501 | $155.30 | $77,805.40 | (9%) 5.74K to 5.24K | |
| 29-Feb-24 4:17 PM View: | Garg Pushkal CMO & EVP Dev & Med Affairs | Alnylam Pharmaceuticals Inc. (ALNY) | 28-Feb-24 | Option Sale | 574 | $155.30 | $89,144.60 | (6%) 9.92K to 9.35K | |
| 29-Feb-24 4:18 PM View: | Tanguler Tolga EVP, Chief Commercial Officer | Alnylam Pharmaceuticals Inc. (ALNY) | 27-Feb-24 | Option Exercise | 1,667 | -- | -- | 41% 4.07K to 5.74K | |
| 29-Feb-24 4:17 PM View: | Garg Pushkal CMO & EVP Dev & Med Affairs | Alnylam Pharmaceuticals Inc. (ALNY) | 27-Feb-24 | Option Exercise | 1,908 | -- | -- | 24% 8.01K to 9.92K | |
| 29-Feb-24 4:18 PM View: | Greenstreet Yvonne Chief Executive Officer Director | Alnylam Pharmaceuticals Inc. (ALNY) | 27-Feb-24 | Option Exercise | 5,921 | -- | -- | 13% 45.55K to 51.47K | |
| 29-Feb-24 4:18 PM View: | Poulton Jeffrey V. EVP, Chief Financial Officer | Alnylam Pharmaceuticals Inc. (ALNY) | 27-Feb-24 | Option Exercise | 1,908 | -- | -- | 10% 18.2K to 20.11K | |
| 29-Feb-24 4:16 PM View: | Franchini Indrani Lall EVP, CLO & Secretary | Alnylam Pharmaceuticals Inc. (ALNY) | 27-Feb-24 | Option Exercise | 878 | -- | -- | 24% 3.58K to 4.46K | |
| 20-Feb-24 4:08 PM View: | Tanguler Tolga EVP, Chief Commercial Officer | Alnylam Pharmaceuticals Inc. (ALNY) | 16-Feb-24 | Sale | 1,009 | $148.06 | $149,397.00 | (20%) 5.08K to 4.07K | |
| 20-Feb-24 4:09 PM View: | Garg Pushkal CMO & EVP Dev & Med Affairs | Alnylam Pharmaceuticals Inc. (ALNY) | 16-Feb-24 | Sale | 1,308 | $148.06 | $193,666.00 | (14%) 9.32K to 8.01K | |
| 20-Feb-24 4:07 PM View: | Greenstreet Yvonne Chief Executive Officer Director | Alnylam Pharmaceuticals Inc. (ALNY) | 16-Feb-24 | Sale | 7,030 | $148.06 | $1,040,880.00 | (13%) 52.58K to 45.55K | |
| 20-Feb-24 4:08 PM View: | Poulton Jeffrey V. EVP, Chief Financial Officer | Alnylam Pharmaceuticals Inc. (ALNY) | 16-Feb-24 | Sale | 1,007 | $148.06 | $149,099.00 | (5%) 19.21K to 18.2K | |
| 20-Feb-24 4:08 PM View: | Tanguler Tolga EVP, Chief Commercial Officer | Alnylam Pharmaceuticals Inc. (ALNY) | 15-Feb-24 | Grant | 3,278 | -- | -- | 182% 1.8K to 5.08K | |
| 20-Feb-24 4:09 PM View: | Garg Pushkal CMO & EVP Dev & Med Affairs | Alnylam Pharmaceuticals Inc. (ALNY) | 15-Feb-24 | Grant | 4,295 | -- | -- | 85% 5.03K to 9.32K | |
| 20-Feb-24 4:07 PM View: | Greenstreet Yvonne Chief Executive Officer Director | Alnylam Pharmaceuticals Inc. (ALNY) | 15-Feb-24 | Grant | 16,953 | -- | -- | 48% 35.62K to 52.58K |
